Translational Pharmacoeconomics in Rare Diseases: Integrating Clinical, Economic, and Social Value in Health Decision-Making
Preprint
- 30 April 2026
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Rare diseases pose a growing challenge for health systems due to the combination of high clinical need, limited evidence, and elevated costs. This article analyzes the intersection between translational medicine and pharmacoeconomics, identifying a structural gap between the clinical value of innovations and traditional economic evaluation frameworks. Drawing on a narrative review of the literature—in which 240 scientific articles were identified and the 30 most methodologically and thematically relevant were selected through systematic screening by title, abstract, and full-text relevance—and a comparative analysis of frameworks in Europe, the United States, and Latin America, we propose the concept of translational pharmacoeconomics as an integrative framework that explicitly incorporates clinical, economic, and social dimensions of value into health decision-making. This approach has direct implications for the design of more equitable, adaptive, and sustainable health policies, particularly in contexts of evidence scarcity and unmet clinical need.Keywords
All Related Versions
This publication has 10 references indexed in Scilit:
- Development and Validation of the TRansparent Uncertainty ASsessmenT (TRUST) Tool for Assessing Uncertainties in Health Economic Decision ModelsPharmacoEconomics, 2019
- Cost-Effectiveness of Combination Therapy Versus Monotherapy in Benign Prostatic Hyperplasia: A Colombian ExperienceValue in Health Regional Issues, 2018
- Defining Elements of Value in Health Care—A Health Economics Approach: An ISPOR Special Task Force Report [3]Value in Health, 2018
- Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL)Orphanet Journal of Rare Diseases, 2017
- Multiple Criteria Decision Analysis for Health Care Decision Making—Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task ForceValue in Health, 2016
- The quality of economic evaluations of ultra-orphan drugs in Europe – a systematic reviewOrphanet Journal of Rare Diseases, 2015
- A Review and Classification of Approaches for Dealing with Uncertainty in Multi-Criteria Decision Analysis for Healthcare DecisionsPharmacoEconomics, 2015
- GENERATING HEALTH TECHNOLOGY ASSESSMENT EVIDENCE FOR RARE DISEASESInternational Journal of Technology Assessment in Health Care, 2014
- The Meaning of Translational Research and Why It MattersJAMA, 2008
- Incorporating societal concerns for fairness in numerical valuations of health programmesHealth Economics, 1999